Top 10 U S Biopharma Clusters genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
Dracen Announces Clinical Collaboration with Merck
Share Article
Dracen will develop sirpiglenastat (DRP-104) in combination with KEYTRUDA® in selected patients with Non-Small Cell Lung Cancer NEW YORK (PRWEB) March 08, 2021 Dracen Pharmaceuticals, Inc. (Dracen) announced today that it has entered into a clinical trial and supply agreement with Merck, known as MSD outside the United States and Canada, to evaluate the safety and efficacy of sirpiglenastat (DRP-104), Dracen’s glutamine antagonist, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with solid tumors.
A Phase 1b trial will enroll locally advanced or metastatic non-small cell lung cancer (NSCLC) patients to establish the safety/tolerability of sirpiglenastat in combination with KEYTRUDA. The trial is expected to begin by first quarter 2022.
UM s Kelly Sexton: Biotech industry continues to thrive, find new solutions
Leisa Thompson
Kelly Sexton is associate vice president for research, technology transfer and innovation partnerships at University of Michigan.
UNIVERSITY OF MICHIGAN: Last May, the University of Michigan inked a $130 million deal with New York City health care investment firm Deerfield Management Co. LP in an effort to ramp up drug commercialization efforts coming out of the Ann Arbor university s tech transfer office. The deal created Great Lakes Discoveries LLC as the vehicle to drive those developments. The partnership is still in the early stages, said
Kelly Sexton, the university s associate vice president for research, technology transfer and innovation partnerships. But it s indicative of the need to grow more biotechnology at the university level and figure out ways to bring it to market, Sexton said.
The Petri Dish: Silicon Therapeutics acquired for $450M, Resilience buys Boston site bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
(Getty Images)
It’s been a relatively quiet few years for FogPharma, at least publicly, but now the Cambridge, Massachusetts-based biotech is revealing a major funding round.
The series C has been pumped up to $107 million from a who’s who of venture capitalists. The round was led by venBio Partners with help from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates Inc., HBM Healthcare Investments, Casdin Capital and PagsGroup.
Existing investors also chipped in, including Google’s GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital.
What has them opening their checkbooks? FogPharma’s platform direct beta-catenin antagonist and universal druggability platform. Out of this has come its lead program, a beta-catenin antagonist designed to treat previously undruggable cancers.